$BCRX
BIOCRYST PHARMACEUTICALS INC

2023 Q4 Form 10-Q Financial Statement

#000162828023037847 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $93.40M $86.74M
YoY Change 17.42% 14.39%
Cost Of Revenue $1.637M $1.099M
YoY Change -34.42% -68.98%
Gross Profit $91.76M $85.64M
YoY Change 19.1% 18.48%
Gross Profit Margin 98.25% 98.73%
Selling, General & Admin $64.38M $50.65M
YoY Change 28.37% 37.19%
% of Gross Profit 70.16% 59.14%
Research & Development $70.05M $46.88M
YoY Change -4.31% -11.11%
% of Gross Profit 76.34% 54.74%
Depreciation & Amortization $423.0K $420.0K
YoY Change 6.82% 7.97%
% of Gross Profit 0.46% 0.49%
Operating Expenses $134.4M $97.53M
YoY Change 8.98% 8.78%
Operating Profit -$42.67M -$11.92M
YoY Change -7.86% -31.67%
Interest Expense -$20.49M $27.35M
YoY Change -18.53% 10.37%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$63.16M -$35.82M
YoY Change -11.62% -12.63%
Income Tax -$1.431M $330.0K
% Of Pretax Income
Net Earnings -$61.73M -$36.15M
YoY Change -13.71% -14.98%
Net Earnings / Revenue -66.09% -41.67%
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$0.31 -$0.19
COMMON SHARES
Basic Shares Outstanding 204.8M shares 189.5M shares
Diluted Shares Outstanding 189.6M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $389.0M $397.6M
YoY Change -8.32% -6.86%
Cash & Equivalents $110.6M $150.9M
Short-Term Investments $278.3M $246.7M
Other Short-Term Assets $21.35M $21.60M
YoY Change 51.84% 72.61%
Inventory $28.68M $29.63M
Prepaid Expenses
Receivables $56.95M $53.65M
Other Receivables $0.00 $0.00
Total Short-Term Assets $496.0M $502.5M
YoY Change -3.98% -1.28%
LONG-TERM ASSETS
Property, Plant & Equipment $7.910M $8.999M
YoY Change -8.2% 6.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $13.08M $11.46M
YoY Change 92.24% 68.59%
Total Long-Term Assets $20.99M $20.46M
YoY Change -37.33% -58.75%
TOTAL ASSETS
Total Short-Term Assets $496.0M $502.5M
Total Long-Term Assets $20.99M $20.46M
Total Assets $517.0M $522.9M
YoY Change -6.01% -6.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.89M $10.57M
YoY Change 45.53% 22.56%
Accrued Expenses $102.9M $77.39M
YoY Change 17.49% 11.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $25.16M
YoY Change
Total Short-Term Liabilities $150.0M $90.76M
YoY Change 42.15% 11.18%
LONG-TERM LIABILITIES
Long-Term Debt $303.2M $298.0M
YoY Change 30.92% 33.11%
Other Long-Term Liabilities $8.390M $10.00M
YoY Change 44.56% 67.56%
Total Long-Term Liabilities $303.2M $298.0M
YoY Change 30.92% 33.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $150.0M $90.76M
Total Long-Term Liabilities $303.2M $298.0M
Total Liabilities $453.2M $388.8M
YoY Change 34.43% 27.25%
SHAREHOLDERS EQUITY
Retained Earnings -$1.681B -$1.619B
YoY Change 15.57% 17.09%
Common Stock $2.058M $1.898M
YoY Change 9.53% 1.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$455.5M -$411.0M
YoY Change
Total Liabilities & Shareholders Equity $517.0M $522.9M
YoY Change -6.01% -6.39%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$61.73M -$36.15M
YoY Change -13.71% -14.98%
Depreciation, Depletion And Amortization $423.0K $420.0K
YoY Change 6.82% 7.97%
Cash From Operating Activities -$8.918M -$19.89M
YoY Change -62.61% -38.69%
INVESTING ACTIVITIES
Capital Expenditures $554.0K $980.0K
YoY Change 5.32% -660.0%
Acquisitions
YoY Change
Other Investing Activities -$27.92M $24.11M
YoY Change -135.91% -134.76%
Cash From Investing Activities -$28.47M $23.11M
YoY Change -136.87% -133.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.173M 1.230M
YoY Change -175.57% -98.39%
NET CHANGE
Cash From Operating Activities -8.918M -19.89M
Cash From Investing Activities -28.47M 23.11M
Cash From Financing Activities -3.173M 1.230M
Net Change In Cash -40.56M 4.450M
YoY Change -170.47% -117.34%
FREE CASH FLOW
Cash From Operating Activities -$8.918M -$19.89M
Capital Expenditures $554.0K $980.0K
Free Cash Flow -$9.472M -$20.87M
YoY Change -61.14% -35.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
0 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
18077000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11459000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6806000 usd
CY2022Q4 us-gaap Assets
Assets
550000000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10567000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14356000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77392000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
87565000 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
522000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1224000 usd
CY2023Q3 bcrx Future Royalties Payable
FutureRoyaltiesPayable
535186000 usd
CY2022Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
501655000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
297995000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
231624000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
189803000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
189803000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1898000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1879000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1205744000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1158118000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
800000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1619428000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1454620000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-410986000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-294597000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
522924000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
550000000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75827000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2924000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4025000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46879000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52740000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146514000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180090000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50648000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36919000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149512000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
109218000 usd
CY2023Q3 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
37000 usd
CY2022Q3 bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
70000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
100000 usd
bcrx Royalty Expense Reversal Of Expense
RoyaltyExpenseReversalOfExpense
73000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
98663000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
93272000 usd
us-gaap Costs And Expenses
CostsAndExpenses
299050000 usd
us-gaap Costs And Expenses
CostsAndExpenses
293406000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11921000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17445000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-102124000 usd
CY2023Q3 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
4184000 usd
CY2022Q3 bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
1760000 usd
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
2423000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
27345000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
24775000 usd
us-gaap Interest Expense
InterestExpense
83656000 usd
CY2023Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-737000 usd
CY2022Q3 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-538000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-665000 usd
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-583000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29019000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172918000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1741000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2657000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-42520000 usd
us-gaap Net Income Loss
NetIncomeLoss
-164808000 usd
us-gaap Net Income Loss
NetIncomeLoss
-175575000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-185000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
695000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-67000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
877000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
295000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-808000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
841000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1152000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42633000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-164034000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-175850000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189644000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189644000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
186180000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
186180000 shares
us-gaap Net Income Loss
NetIncomeLoss
-164808000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1232000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1041000 usd
us-gaap Inventory Write Down
InventoryWriteDown
236000 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
39127000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
29419000 usd
bcrx Noncash Interest Expense And Amortization Of Debt Issuance Costs
NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
55119000 usd
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
-6814000 usd
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
-818000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29019000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2357000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7530000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1132000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-36678000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-27639000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
306239000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
507734000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2023#LongTermInvestments
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2023#LongTermInvestments
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q3 us-gaap Assets
Assets
522924000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
187906000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187906000 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-61039000 usd
bcrx Interest And Other Income Loss
InterestAndOtherIncomeLoss
11312000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36039000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189095000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189095000 shares
us-gaap Net Income Loss
NetIncomeLoss
-175575000 usd
bcrx Noncash Interest Expense And Amortization Of Debt Issuance Costs
NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
66286000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
6345000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-811000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
329000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86223000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-138001000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1614000 usd
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
825000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
357419000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
244283000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
256008000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
39655000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-103025000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-205453000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8518000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10756000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
300000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
73072000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
240452000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
21261000 usd
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
11147000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35658000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83828000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-160000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-153750000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-259391000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
152489000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
248343000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-294597000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-53333000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
559000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
176000 shares
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1575000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
801000 shares
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3502000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14007000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
105000 usd
CY2023Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
608000 shares
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12841000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-388713000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-36149000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
110000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
162000 shares
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1020000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
149000 shares
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
467000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12279000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-410986000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-106986000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74196000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
115000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1504000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1108000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5853000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9601000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1584000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-164215000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-58859000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-171000 usd
CY2022Q2 bcrx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
253000 shares
CY2022Q2 bcrx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3000 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
51000 shares
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9865000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-213232000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-42520000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-113000 usd
CY2022Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
145000 shares
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1357000 usd
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
390000 shares
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1896000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9953000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-242659000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s condensed consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75827000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
238011000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
191282000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1472000 usd
bcrx Long Term Investment Maturity Minimum
LongTermInvestmentMaturityMinimum
P12M
CY2023Q3 us-gaap Inventory Adjustments
InventoryAdjustments
170000 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1347000 usd
CY2023Q3 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
230000 usd
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
1536000 usd
CY2022Q3 bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
258000 usd
bcrx Amortization Of Debt Financing Costs And Original Issue Discounts
AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
597000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
54772000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50430000 shares
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
CY2023Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
CY2022Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86742000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75827000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
246685000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
137620000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
24 securities
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
215095 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
246858000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
49000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
225000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
246685000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
138196000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
487000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1063000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
137620000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
246685000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
119543000 usd
CY2023Q3 bcrx Maturing After One Year Through Two Years
MaturingAfterOneYearThroughTwoYears
0 usd
CY2022Q4 bcrx Maturing After One Year Through Two Years
MaturingAfterOneYearThroughTwoYears
18077000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
246685000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
137620000 usd
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1677000 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8268000 usd
CY2022Q4 bcrx Future Royalties Payable
FutureRoyaltiesPayable
501655000 usd
CY2023Q1 bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
19318000 usd
CY2023Q1 bcrx Royalties Revenues Paid And Payable
RoyaltiesRevenuesPaidAndPayable
-6562000 usd
CY2023Q1 bcrx Future Royalties Payable
FutureRoyaltiesPayable
514411000 usd
CY2023Q2 bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
19486000 usd
CY2023Q2 bcrx Royalties Revenues Paid And Payable
RoyaltiesRevenuesPaidAndPayable
-7776000 usd
CY2023Q2 bcrx Future Royalties Payable
FutureRoyaltiesPayable
526121000 usd
CY2023Q3 bcrx Non Cash Interest Expense On Royalty Financing Obligation
NonCashInterestExpenseOnRoyaltyFinancingObligation
17272000 usd
CY2023Q3 bcrx Royalties Revenues Paid And Payable
RoyaltiesRevenuesPaidAndPayable
-8207000 usd
CY2023Q3 bcrx Future Royalties Payable
FutureRoyaltiesPayable
535186000 usd
bcrx Amortization Of Debt Issuance Costs Net Of Pik Interest
AmortizationOfDebtIssuanceCostsNetOfPIKInterest
1069000 usd
bcrx Amortization Of Debt Issuance Costs Net Of Pik Interest
AmortizationOfDebtIssuanceCostsNetOfPIKInterest
-597000 usd
CY2023Q3 bcrx Aggregate Lease Expense
AggregateLeaseExpense
1014000 usd
CY2022Q3 bcrx Aggregate Lease Expense
AggregateLeaseExpense
634000 usd
bcrx Aggregate Lease Expense
AggregateLeaseExpense
2505000 usd
bcrx Aggregate Lease Expense
AggregateLeaseExpense
1854000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11380000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6806000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2282000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2369000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9966000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5804000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12248000 usd
CY2023Q3 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
6350000 usd
CY2022Q4 bcrx Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
4349000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
834000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1796000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
853000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3279000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2332000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1846000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1531000 usd
CY2023Q3 bcrx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
9292000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19133000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6885000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12248000 usd
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
72360000 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
67238000 shares
CY2023Q3 bcrx Share Based Payment Arrangement Number Of Plans
ShareBasedPaymentArrangementNumberOfPlans
3 plan
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39127000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29421000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
111804000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
338000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
260000 shares
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-23-037847-index-headers.html Edgar Link pending
0001628280-23-037847-index.html Edgar Link pending
0001628280-23-037847.txt Edgar Link pending
0001628280-23-037847-xbrl.zip Edgar Link pending
bcrx-20230930.htm Edgar Link pending
bcrx-20230930.xsd Edgar Link pending
bcrx-20230930xexx311.htm Edgar Link pending
bcrx-20230930xexx312.htm Edgar Link pending
bcrx-20230930xexx321.htm Edgar Link pending
bcrx-20230930xexx322.htm Edgar Link pending
exhibit102-inducementequit.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
bcrx-20230930_cal.xml Edgar Link unprocessable
bcrx-20230930_def.xml Edgar Link unprocessable
bcrx-20230930_lab.xml Edgar Link unprocessable
bcrx-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcrx-20230930_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending